Advanced medullary thyroid cancer: pathophysiology and management

Area of Science:

• Oncology
• Genetics
• Endocrinology

Background:

• Medullary thyroid carcinoma (MTC) is a rare malignancy originating from thyroid parafollicular C cells, comprising 3%-4% of thyroid neoplasms.
• MTC can be sporadic or inherited, with hereditary forms linked to multiple endocrine neoplasia syndromes (MEN2A, MEN2B) or familial MTC, caused by germ-line mutations in the RET proto-oncogene.
• The RET gene encodes a receptor tyrosine kinase crucial for cell proliferation, growth, differentiation, migration, and survival, making it a key target in MTC pathogenesis.

Purpose of the Study:

• To review the current understanding of medullary thyroid carcinoma (MTC) pathogenesis.
• To highlight the role of the RET proto-oncogene in MTC development.
• To discuss emerging therapeutic strategies, particularly small-molecule tyrosine kinase inhibitors, for MTC treatment.

Main Methods:

• Literature review of MTC pathogenesis, genetics, and treatment modalities.
• Analysis of the role of RET proto-oncogene mutations in sporadic and hereditary MTC.
• Evaluation of clinical trial data for tyrosine kinase inhibitors in MTC management.

Main Results:

• Germ-line RET mutations cause hereditary MTC, while somatic mutations are found in sporadic cases.
• Early diagnosis and total thyroidectomy remain the primary curative options for MTC.
• Small-molecule tyrosine kinase inhibitors have demonstrated encouraging results in clinical trials for metastatic MTC.

Conclusions:

• Understanding MTC's molecular mechanisms, especially RET signaling, is vital for targeted therapy development.
• Tyrosine kinase inhibitors represent a promising therapeutic avenue for advanced or metastatic MTC.
• Further research into drug targets and side effect management will optimize tyrosine kinase inhibitor therapy for MTC.